Physician profile
John Andrews
NPI 1447262126
$6,759.80
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2021: $53.66 · 2022: $190 · 2023: $6,130 · 2024: $262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,819 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,950 · Food and Beverage: $623.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,818.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,950.00 |
| Food and Beverage | $622.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $5,768.75 | 2023 | Quartex |
| Lilly USA, LLC | $147.14 | 2022-2024 | Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $124.97 | 2019 | |
| Novartis Pharmaceuticals Corporation | $119.48 | 2022-2024 | |
| Amgen INC. | $102.20 | 2023-2024 | Evenity, Prolia, Tepezza |
| Glaxosmithkline, LLC. | $70.10 | 2023-2024 | Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $65.29 | 2023 | Breztri |
| Otsuka America Pharmaceutical, INC. | $59.88 | 2023 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.76 | 2022-2024 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $49.11 | 2022 | |
| Medtronic, INC. | $27.85 | 2022 | |
| Novo Nordisk INC | $27.55 | 2022-2024 | |
| Teva Pharmaceuticals USA, INC. | $27.24 | 2021 | |
| Exact Sciences Corporation | $27.19 | 2023 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $26.42 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $25.63 | 2023 | |
| Pfizer INC. | $21.64 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $12.60 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Andrews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.